Humacyte To Present Phase 3 Results Comparing Efficacy And Safety Of Tissue-Engineered Vessel To AV Fistulas In End-Stage Renal Disease Patients At VEITH Symposium On November 23, 2024

BenzingaNov 22 08:02 ET

Humacyte to Present Efficacy and Safety Results From V007 Phase 3 AV Access Clinical Trial at the 51st Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITH)

GlobeNewswireNov 22 08:00 ET

TD Cowen Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $10

Moomoo NewsNov 21 11:31 ET · Ratings

Insider Buyers At Humacyte Likely Disappointed With 17% Slide

Yahoo FinanceNov 21 11:15 ET

Promising Clinical Outcomes and Imminent FDA Approval Bolster Buy Rating for Humacyte's Bioengineered Vessel

TipRanksNov 21 11:05 ET · Ratings

Insider Sale: President of $HUMA (HUMA) Sells 427,459 Shares

Quiver QuantitativeNov 20 19:16 ET